314 related articles for article (PubMed ID: 27913517)
21. Management of lower-risk myelodysplastic syndromes: the art and evidence.
Komrokji RS; Sekeres MA; List AF
Curr Hematol Malig Rep; 2011 Jun; 6(2):145-53. PubMed ID: 21442178
[TBL] [Abstract][Full Text] [Related]
22. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
24. [Management of lower-risk myelodysplastic syndromes].
Ichikawa M
Rinsho Ketsueki; 2020; 61(9):1212-1217. PubMed ID: 33162518
[TBL] [Abstract][Full Text] [Related]
25. How we manage adults with myelodysplastic syndrome.
Fenaux P; Platzbecker U; Ades L
Br J Haematol; 2020 Jun; 189(6):1016-1027. PubMed ID: 31568568
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G; Chien KS; Montalban-Bravo G
Am J Hematol; 2020 Nov; 95(11):1399-1420. PubMed ID: 32744763
[TBL] [Abstract][Full Text] [Related]
27. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA; Taylor J
JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
[TBL] [Abstract][Full Text] [Related]
28. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Zeidan AM; Gore SD; McNally DL; Baer MR; Hendrick F; Mahmoud D; Davidoff AJ
Cancer; 2013 Nov; 119(21):3870-8. PubMed ID: 23922173
[TBL] [Abstract][Full Text] [Related]
30. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF
J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091
[TBL] [Abstract][Full Text] [Related]
31. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
32. SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes.
Volpe VO; Garcia-Manero G; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2023 Mar; 23(3):168-177. PubMed ID: 36682988
[TBL] [Abstract][Full Text] [Related]
33. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
Leitch HA; Buckstein R; Shamy A; Storring JM
Crit Rev Oncol Hematol; 2013 Feb; 85(2):162-92. PubMed ID: 22901762
[TBL] [Abstract][Full Text] [Related]
34. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
35. Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes.
Wang C; Sallman DA
Curr Treat Options Oncol; 2023 May; 24(5):387-408. PubMed ID: 36966266
[TBL] [Abstract][Full Text] [Related]
36. Myelodysplastic syndromes current treatment algorithm 2018.
Steensma DP
Blood Cancer J; 2018 May; 8(5):47. PubMed ID: 29795386
[TBL] [Abstract][Full Text] [Related]
37. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
38. Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes.
Hattakitpanitchakul S; Kobbuaklee S; Wudhikarn K; Polprasert C
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4037-4042. PubMed ID: 34967586
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.
Burgstaller S; Wiesinger P; Stauder R
Drugs Aging; 2015 Nov; 32(11):891-905. PubMed ID: 26476843
[TBL] [Abstract][Full Text] [Related]
40. First-line Therapeutic Strategies for Myelodysplastic Syndromes.
Santini V
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S31-S36. PubMed ID: 28760300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
